Jackson Center, PA, August 27, 2020 – Halberd Corp. (OTC PINK: "HALB") is pleased to announce the successful completion of its search for a major research university partner. The University, to be announced, is engaged to develop compounds for use in Halberd’s patented extracorporeal treatment of Covid-19. Terms of the agreement have been finalized and ...
Jackson Center, PA, July 16, 2020 – Halberd Corp. (OTC PINK: "HALB") intends to use laser technology to eradicate the COVID-19 Coronavirus. This patent pending treatment introduces one or more fluorescent antibody-antigen complexing agents to bind with the target antigen(s) (i.e., Covid-19 target antigens). This will allow the virus to be seen and located, and ...
Jackson Center, PA, July 13, 2020 – Halberd Corp. (OTC PINK: "HALB") today issued a statement to clarify certain items within its charter regarding allowable debt. There have been inaccurate rumors that have put the company in a negative light. One of these is that the company intends to take on convertible debt. Nothing could ...
Jackson Center, PA, July 7, 2020 – Halberd Corp. (OTC PINK: "HALB") today explains the second of three (3) COVID -19 (Coronavirus) patent pending treatments - “Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients” - which was filed with the U.S. Patent and Trademark Office on ...